Eplontersen vs Vutrisiran

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Transthyretin Amyloidosis with Cardiomyopathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Cardiomyopathy pipeline

Eplontersen · Wainua

Marketed by AstraZeneca and partners

Phase 3 in Transthyretin Amyloidosis with Cardiomyopathyantisense
Partial signal

NCT04136171 · Phase 3 · completed

This was a large randomized, double-blind, placebo-controlled trial of 1,432 treated patients with a hard clinical primary endpoint, cardiovascular death and recurrent cardiovascular events. Eplontersen did not reduce this endpoint significantly compared with placebo, so the trial is well-designed evidence of no clear benefit rather than strong evidence of a positive effect.

Next expected readout: August 2029 · NCT05667493 (registry estimate)

Reported efficacy

Composite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140 (Baseline up to Week 140): CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. (missed)

Result source: NCT04136171

Vutrisiran · AMVUTTRA

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with CardiomyopathyRNAi
Reliable signal

NCT04153149 · Phase 3 · active, not recruiting

HELIOS-B randomised 655 patients with transthyretin amyloid cardiomyopathy to vutrisiran or placebo under quadruple masking. Both primary analyses of the clinical composite endpoint (all-cause death and recurrent cardiovascular events) were met: HR 0.718 (p=0.0118) in the overall population and HR 0.672 (p=0.0162) in the monotherapy subgroup.

Next expected readout: March 2028 · NCT06679946 (registry estimate)

Reported efficacy

Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular (CV) Events (CV Hospitalizations and Urgent Heart Failure [HF] Visits) in the Overall Population (Up to Month 36); Composite Endpoint of All-Cause Mortality and Recurrent CV Events (CV Hospitalizations and Urgent HF Visits) in the Vutrisiran Monotherapy Subgroup (Up to Month 36): Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 (met)

Result source: NCT04153149

Results for Transthyretin Amyloidosis with Cardiomyopathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Eplontersen
CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. NCT04136171 · Phase 3 · design grade: moderate · publication or press release
Vutrisiran
Composite of all-cause mortality and recurrent cardiovascular events: overall population HR 0.718 (95% CI 0.555 to 0.929), p=0.0118; vutrisiran monotherapy subgroup HR 0.672 (95% CI 0.487 to 0.929), p=0.0162 NCT04153149 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

Transthyretin Amyloidosis with Polyneuropathy

Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline

Eplontersen · Wainua

Marketed by AstraZeneca and partners

Approved in Transthyretin Amyloidosis with Polyneuropathyantisense
Weak signal

NCT04136184 · Phase 3 · completed

This open-label Phase 3 trial randomized 168 people with hereditary transthyretin amyloid polyneuropathy 6:1 to eplontersen or inotersen, but the primary efficacy comparisons were made between the eplontersen group and an external placebo group from an earlier, separate trial (NEURO-TTR). At Week 66 eplontersen was favored on neuropathy impairment (mNIS+7, LS mean difference -24.76, 95% CI -30.96 to -18.56) and on Norfolk quality of life (-19.74, 95% CI -25.63 to -13.84), and serum TTR fell by 70.42 percentage points more at Week 65, all with p<0.0001. Because the comparison group was neither randomized nor treated within this study, and no one was blinded, these results are more open to bias than a concurrent placebo-controlled comparison.

No aligned efficacy figure on record for this race.

Vutrisiran · AMVUTTRA

Marketed by Alnylam Pharmaceuticals

Approved in Transthyretin Amyloidosis with PolyneuropathyRNAi
Partial signal

NCT03759379 · Phase 3 · completed

This was a randomized but open-label study, and its primary comparison used 122 vutrisiran-treated participants versus 77 participants from an external APOLLO placebo group rather than a concurrent blinded placebo arm. The clinical primary endpoint, change in mNIS+7 at Month 9, favored vutrisiran and was statistically significant, but the lack of blinding and use of an external comparator limit the strength of the evidence.

Reported efficacy

Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) (met)

Result source: NCT03759379

Results for Transthyretin Amyloidosis with Polyneuropathy

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Eplontersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Vutrisiran
Change From Baseline in the Modified Neurologic Impairment Score +7 (mNIS+7) at Month 9 Between the Vutrisiran Group (HELIOS-A) and the External Placebo Comparator Group [APOLLO (NCT01960348)] (Baseline, Month 9): External Placebo Comparator (APOLLO) 14.76 score on a scale (Standard Error 2) | Vutrisiran + Vutrisiran (HELIOS-A) -2.24 score on a scale (Standard Error 1.43) NCT03759379 · Phase 3 · design grade: moderate · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eplontersen's landscape · Vutrisiran's landscape